# Nimodipine PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/nimodipine

> Nimodipine, sponsored by Grace Therapeutics, Inc. (GRCE), received a complete response letter from the FDA; the decision is dated July 28, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is nimodipine FDA approved?

Not as of November 16, 2026. Nimodipine, sponsored by Grace Therapeutics, Inc. (GRCE), received a complete response letter from the FDA; the decision is dated July 28, 2026. Press release filed with the SEC (EX-99): "Princeton, NJ, July 28, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced receipt of the U.S. Food and Drug Administration (FDA) meeting minutes from a Type A Meeting held with the FDA to discuss the Complete Response Letter (CRL) issued on April 23, 2026." [Calendar and source filings](https://sec-api.dev/pdufa/nimodipine)

Source: Press release filed with the SEC (EX-99), accession 0001140361-26-029837, https://www.sec.gov/Archives/edgar/data/1444192/000114036126029837/ef20078866_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-07-28. Cite: https://sec-api.dev/pdufa/nimodipine#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | nimodipine |
| Codes |  |
| Sponsor | Grace Therapeutics, Inc. (GRCE) https://sec-api.dev/companies/grce/catalysts |
| Indications | [with asah](https://sec-api.dev/indications/with-asah) |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Sep 2021: trial start

- Status: completed. Date confidence: month.
- First seen 2024-11-13, last confirmed 2024-11-13.
- SEC Form 10-Q (accession 0001140361-24-046312): "In September 2021, we initiated our pivotal PK bridging trial to evaluate the relative bioavailability of GTx-104 compared to currently marketed oral nimodipine capsules in approximately 50 healthy subjects." https://www.sec.gov/Archives/edgar/data/1444192/000114036124046312/ef20037228_10q.htm

### Q1 2025: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2024-11-13, last confirmed 2024-11-13.
- Press release filed with the SEC (EX-99) (accession 0001140361-24-046314): ""With enrollment in the STRIVE-ON trial now complete, we anticipate a data readout in first calendar quarter of 2025, and remain on track to submit a New Drug Application (NDA) to the U.S. Food Drug Administration in the first half of calendar 2025." https://www.sec.gov/Archives/edgar/data/1444192/000114036124046314/ef20038398_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-24-046314): "We anticipate a data readout from the STRIVE-ON trial in the first calendar quarter of 2025." https://www.sec.gov/Archives/edgar/data/1444192/000114036124046314/ef20038398_ex99-1.htm

### August 27, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2025-08-27, last confirmed 2026-02-12.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-032847): "Princeton, NJ, August 27, 2025 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that on August 22, 2025 the U.S. Food and Drug Administration (FDA) accepted the Company's New Drug Application (NDA) for GTx-104 for formal review." https://www.sec.gov/Archives/edgar/data/1444192/000114036125032847/ef20054617_ex99-1.htm
- SEC Form 10-Q (accession 0001140361-26-004924): "On August 22, 2025 the FDA accepted our NDA for review and established April 23, 2026 as the Prescription Drug User Fee Act (PDUFA) target date for completing its review of our submission." https://www.sec.gov/Archives/edgar/data/1444192/000114036126004924/ef20060621_10q.htm
- SEC Form 10-Q (accession 0001140361-25-041804): "On August 22, 2025 the FDA accepted our NDA for review and established April 23, 2026 as the Prescription Drug User Fee Act (PDUFA) target date for completing its review of our submission." https://www.sec.gov/Archives/edgar/data/1444192/000114036125041804/ef20054994_10q.htm

### April 23, 2026: NDA/BLA submission

- Status: scheduled. Date confidence: exact.
- First seen 2025-08-27, last confirmed 2025-08-27.
- SEC Form 8-K (accession 0001140361-25-032847): "The FDA established a Prescription Drug User Fee Act (PDUFA) target date of April 23, 2026 for its review of the Company's NDA submission." https://www.sec.gov/Archives/edgar/data/1444192/000114036125032847/ef20054617_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-032847): "Act (PDUFA) target date of April 23, 2026 for its review of the Company's NDA submission." https://www.sec.gov/Archives/edgar/data/1444192/000114036125032847/ef20054617_ex99-1.htm

### April 23, 2026: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: with aSAH.
- First seen 2026-04-23, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001140361-26-016324): "Princeton, NJ, April 23, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's New Drug Application (NDA) for GTx-104 for the treatment of patients with aSAH." https://www.sec.gov/Archives/edgar/data/1444192/000114036126016324/ef20070593_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-043308): "Announced receipt of the FDA meeting minutes from a Type A Meeting held with the FDA to discuss the CRL issued on April 23, 2026." https://www.sec.gov/Archives/edgar/data/1444192/000114036126043308/ef20085030_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-032644): "Announced receipt of the FDA meeting minutes from a Type A Meeting held with the FDA to discuss the CRL issued on April 23, 2026." https://www.sec.gov/Archives/edgar/data/1444192/000114036126032644/ef20079525_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-025667): ""Since receipt of the U.S. Food and Drug Administration's (FDA) Complete Response Letter (CRL) in April 2026, we have been working diligently on addressing the cited items, and we look forward to a constructive discussion with the FDA as we continue to prepare our resubmission," said Prashant Kohli, CEO of Grace Therapeutics." https://www.sec.gov/Archives/edgar/data/1444192/000114036126025667/ef20076145_ex99-1.htm

### July 28, 2026: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-07-28, last confirmed 2026-07-28.
- Press release filed with the SEC (EX-99) (accession 0001140361-26-029837): "Princeton, NJ, July 28, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced receipt of the U.S. Food and Drug Administration (FDA) meeting minutes from a Type A Meeting held with the FDA to discuss the Complete Response Letter (CRL) issued on April 23, 2026." https://www.sec.gov/Archives/edgar/data/1444192/000114036126029837/ef20078866_ex99-1.htm

## Same indication

- [GTX-104](https://sec-api.dev/pdufa/gtx-104) (GRCE)

Calendar months: [April 2026](https://sec-api.dev/fda-calendar/2026-04)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/nimodipine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Nimodipine PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/nimodipine

```bibtex
@misc{secapidev_pdufa_nimodipine_20261116,
  title        = {Nimodipine PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/nimodipine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_nimodipine_20261116","title":"Nimodipine PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/nimodipine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
